107 118

Cited 4 times in

Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer

Authors
 Min Joo Kim  ;  Seok-Mo Kim  ;  Eun Kyung Lee  ;  Yul Hwangbo  ;  You Jin Lee  ;  Sun Wook Cho  ;  Do Joon Park  ;  Yumi Lee  ;  Young Joo Park 
Citation
 Endocrine Journal, Vol.66(7) : 597-604, 2019 
Journal Title
 Endocrine Journal 
ISSN
 0918-8959 
Issue Date
2019
Keywords
Efficacy ; Sorafenib ; Thyroid cancer ; Thyroid neoplasm ; Tumor doubling time
Abstract
Sorafenib has emerged as an effective therapeutic option for radioactive iodine (RAI)-refractory, locally advanced or metastatic differentiated thyroid cancer (DTC). We investigated the efficacy and safety of sorafenib treatment in a real-world setting and unveil predictive markers of responsiveness to sorafenib. The treatment response, progression-free survival (PFS), overall survival, and adverse events (AEs) of sorafenib-treated RAI-refractory, locally advanced or metastatic DTC patients at three institutes were retrospectively reviewed, and their tumor doubling time was calculated by three investigators. Total eighty-five patients were treated with sorafenib, and seven patients discontinued sorafenib due to AEs before the first tumor assessment. The median PFS was 14.4 months, and the objective response rate was 10.3% in 78 patients who were able to evaluate the tumor response. Age, sex, histologic type, tumor location, RAI avidity, or the presence of FDG-PET uptake did not affect PFS. However, smaller tumor size (≤1.5 cm) of the target lesions in lung showed better PFS (hazard ratio [HR] 0.39, p = 0.01), and tumors with the shortest doubling time (≤6 months) had worse outcome (HR 2.70, p < 0.01). Because of AEs, dose reductions or drug interruptions were required in 64% of patients, and eventually, 23% of patients discontinued sorafenib permanently. The most common AE was hand-foot skin reaction (HFSR). Patients with severe HFSR showed better PFS, but there were no statistical significance (HR 0.65, p = 0.05). In conclusion, small tumor size and long doubling time of each target lesion can be a prognostic marker to predict the responsiveness to sorafenib in RAI-refractory DTC patients.
Files in This Item:
T201902953.pdf Download
DOI
10.1507/endocrj.EJ18-0488
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Seok Mo(김석모) ORCID logo https://orcid.org/0000-0001-8070-0573
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/171129
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links